Evaluation of triterpenes derivatives in the viability of Leishmania amazonensis and Trichomonas vaginalis by Cargnin, Simone Tasca et al.
Braz. J. Pharm. Sci. 2019;55:e17481 Page 1 / 7







*Correspondence: S. C. B. Gnoatto. Laboratório de Fitoquímica e Síntese 
Orgânica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul 
(UFRGS), Porto Alegre, Rio Grande do Sul (RS), Brasil. Tel.: (51) 3308-54.51; 
Fax: (51) 3308-53.13. E-mail: simone.gnoatto@ufrgs.br
Evaluation of triterpenes derivatives in the viability of 
Leishmania amazonensis and Trichomonas vaginalis
Simone Tasca Cargnin1, Andressa Finkler Staudt1, Camila Menezes1, Ana Paula de Azevedo2, 
Saara Neri Fialho2, Tiana Tasca1, Carolina Bioni Garcia Teles2, Simone Baggio Gnoatto 1,*
1School of Pharmacy, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil, 2Malaria and 
Leishmaniasis Bioassays Platform, Fiocruz, Porto Velho, RO, Brazil.
Trichomonas vaginalis and Leishmania spp. are protozoal species responsible for millions of cases of 
parasitic diseases worldwide. Considering the potential of natural products and the need for more effective 
and less toxic alternatives to treat trichomoniasis and leishmaniasis, this study aimed to evaluate the effect 
of two series of triterpenes derivatives with different modifications at C-3 and C-28 positions of the ursolic 
acid (UA) and betulinic acid (BA) against trophozoites of Trichomonas vaginalis and promastigotes 
forms of Leishmania (L.) amazonensis. The compounds modified just at C-3 were the most active. The 
3β-acetyl betulinic acid (1b) reduced the trophozoites viability of T. vaginalis at 74%, followed by the 
3-oxo ursolic acid and 3-oxo betulinic acid (3a and 3b) compounds (55% of reduction). The compound 
3β-isobutyl ursolic acid (7a) inhibited the viability of L. amazonensis promastigotes by 55%. Therefore, 
analyzing the structure-activity relationship and the data of literature, it is possible to suppose that the 
inclusion of polar groups in the skeletons could improve the antiprotozoal activity. Overall, further studies 
are necessary to develop triterpenic derivatives with more powerful trichomonicidal and leishmanicidal 
properties. 
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INTRODUCTION
Human pathogens, such as Trichomonas vaginalis 
and Leishmania spp., are unicellular eukaryotes (protists) 
representative of the supergroup Excavata that includes 
a few other parasites such as Trypanosoma and Giardia. 
These protozoa are responsible for a broad range of health 
diseases around the world, mainly in the developing 
countries (Kusdian, Gould, 2015).
Trichomonas vaginalis is a microaerophilic mucosal 
pathogen, which affects the human urogenital tract causing 
trichomoniasis, the most common non-viral sexually 
transmitted disease (STD) in the world (WHO, 2012). 
According to the World Health Organization (2012), 
there are about 276 million new cases of trichomoniasis 
annually worldwide. The parasite mainly affects the 
urogenital tract of both men and women, and it may cause 
asymptomatic infection or lead to urethritis or vaginitis. 
Studies have indicated several complications related to 
this disease, including amplification of HIV transmission, 
risk of low birth weight, and preterm delivery (Schwebke, 
Burgess, 2004). The Food and Drug Administration (FDA, 
USA) recommends the treatment for trichomoniasis with 
a few drugs of choice belonging to 5-nitroimidazole class, 
with metronidazole and tinidazole - the only two approved 
drugs. Besides the side effects observed during treatment, 
another important limitation regarding the nitroimidazoles 
administration is the emergence of metronidazole-
resistant isolates estimated in 2.5 to 10%. The reliance on 
a single therapeutic class is problematic and alternative 
treatments are urgently needed (Klebanoff et al., 2001; 
Cudmore et al., 2004).
Leishmaniasis are neglected infectious diseases 
caused by protozoan belonging to the genus Leishmania, 
and are transmitted via the bites of infected female 
phlebotomines. There are three main forms of the 
disease: visceral, cutaneous, and mucocutaneous 
(Silveira, Lainson, Corbett, 2004; WHO, 2018). An 
estimated 700,000 to 1 million new cases and 20,000 
to 30,000 deaths occur annually around the world, still 
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being a serious disease in tropical and subtropical areas 
(WHO, 2018). There are more than 20 Leishmania species 
that are transmitted to humans, among them Leishmania 
(L.) amazonensis (Lainson, 2010). This species is 
the most widely distributed in Brazil and can cause 
mucocutaneous leishmaniasis, which ranges from small 
cutaneous nodules to gross mucosal tissue destruction 
(Silveira, 2009; Machado, Penna, 2012). The type of 
disease, parasite species, and the immunological status 
of the host defines the treatment of leishmaniasis. The 
pentavalent antimonials, pentamidine, amphotericin B, 
paromomycin, and miltefosine are the drugs available for 
disease treatment; however, they all have limitations such 
as high costs, specific toxicity, the emergence of resistance 
and the need for parenteral administration. In this scenario, 
the discovery and development of new effective drugs is 
imperative; nevertheless, leishmaniasis is one of the most 
neglected tropical diseases in terms of drug discovery 
(Singh et al., 2014; Rajasekaran, Chen, 2015).
Taking into account the need for more effective 
and safer alternatives to treat trichomoniasis and 
leishmaniasis, and the rich structural diversity of natural 
products, research with focus on the investigation of 
natural products with activity against these protozoa 
have increased. A recent review referring to the potential 
of natural and synthetic products with anti-trichomonal 
activity, demonstrated that terpenes, phenolic compounds, 
and alkaloids are promising potential compounds against 
T. vaginalis (Vieira et al., 2015). Likewise, it has been 
demonstrated for Leishmania, that quinones, alkaloids, 
terpenes, saponins, phenolic and their derivatives 
have shown antiparasitic properties and selective 
pharmacological properties modes of action (Singh et al., 
2014). 
Considering the potential of the natural products 
and that research of therapeutic alternatives for parasitic 
diseases are needed, this study aimed to evaluate the 
activity of two series of semisynthetic derivatives with 
different modifications at C-3 and C-28 positions of 
the triterpenes ursolic acid and betulinic acid against 
trophozoites of T. vaginalis and promastigotes forms of 
Leishmania (L.) amazonensis.
MATERIAL AND METHODS 
Ursolic and betulinic acids extraction 
Betulinic acid (BA) was obtained from barks of 
Platanus acerifolia, collected in Bento Gonçalves, RS, 
Brazil (29°10’40.43”S 51°34’2.2”W). Ursolic acid (UA) 
was isolated from apple pomace (Malus domestica); a 
by-product of juice manufacture Tecnovin Ltd., Bento 
Gonçalves, RS, Brazil (Cargnin, Gnoatto, 2017). The 
triterpenes identities were confirmed by spectroscopic 
comparison with analytical standard and related literature 
(Tkachev et al., 1994).
Semisynthesis of UA and BA series
Briefly, compounds modified at C-3 position were 
prepared by the reaction of UA or BA with the appropriate 
anhydride or oxidizing agent, as previously described 
(Gnoatto et al., 2008b; Silva et al., 2013). Derivatives with 
ester or ketone substituents at C-3 were then submitted to 
another reaction for modifications at C-28, and methyl 
and imidazole ring at C-28 were incorporated (Scheme 
1). The derivatives identities were confirmed by analysis 
of spectroscopic data (IR, 1H-NMR and 13C-NMR spectra 
and Mass spectra – LC-MS), and compared with data of 
literature (Santos et al., 2009; Leal et al., 2012; Silva et al., 
2013).
Biological evaluation
In vitro anti-Trichomonas vaginalis activity
Trichomonas vaginalis isolate (ATCC 30236) were 
cultured axenically in vitro in trypticase-yeast extract-
maltose (TYM) medium (pH 6.0), supplemented with 10% 
heat-inactivated bovine serum (HIBS), and incubated at 37 
°C (Diamond, 1957). Organisms in the logarithmic phase 
of growth and exhibiting more than 95% viability and 
normal morphology were harvested, centrifuged, washed 
and resuspended in fresh TYM medium. To perform 
the screening assay, the compounds were solubilized in 
dimethyl sulfoxide (DMSO) (0.6%) at final concentrations 
of 100 µM. The trophozoites were incubated at a density 
of 2.0×105 trophozoites/mL, at 37 °C for 24 h.  The 
T. vaginalis viability was determined by counting in 
hemocytometer using trypan blue as exclusion dye. A 
negative control with trophozoites maintained in TYM 
medium, a control of the vehicle, and a positive control 
(metronidazole 8.0 μM) were carried out. The results were 
expressed as the percentage of living parasites after 24 h 
of the incubation period considering motility and normal 
morphology (percentage of living organisms compared to 
negative control). 
In vitro anti-Leishmania amazonensis activity
Promas t igo tes  Leishmania  (Le i shmania) 
amazonensis (IFLA/67/BR/PH8) were cultured in vitro 
at 23 °C in RPMI medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 20 mM Hepes 
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(N-2-ydroxyetrylpiperazine-N’-2-ethanesulfonic acid), 
and 50 mg/mL of gentamycin and subcultured every 
96 h. The anti-L. amazonensis activity of compounds 
was determined by measure of viability of promastigotes 
forms by MTT assay (Pal et al., 2011), with modifications. 
For these experiments, promastigotes in stationary phase 
were seeded at 1.0×106 parasite/100µL/well in 96-well 
plates in complete RPMI medium with compounds at 
final concentration of 100 µM, solubilized in DMSO 
(0.6%). Pentamidine (9.0 µM) was used as reference anti-
leishmanial agent. Promastigotes were incubated at 23 ºC 
for 72 h. Afterwards, 10 μL of a MTT solution (5 mg/mL in 
phosphate buffered saline - PBS) was added to each well and 
incubated for further 4 h at 23 °C. Subsequently, 100 µL of 
DMSO was added to each well and was incubated for 1 h at 
room temperature. The optical density (OD) was measured 
at 540 nm. The results are expressed as percentage of viable 
promastigotes, compared with controls. 
In vitro cytotoxicity assay 
Cell viability was determined by a colorimetric 
method (Mosmann, 1983), using VERO (African Green 
Monkey Kidney, ATCC CCL-81) cells and MTT reagent 
(Sigma-Aldrich, USA). Briefly, VERO cells were 
cultured in RPMI 1640 (Sigma) supplemented with 10% 
FBS, 20 mmol/L Hepes, and 50 mg/mL of gentamycin. 
Experiments were performed in 96-well microtiter 
plates, where a suspension of 1.0×104 cells per well was 
incubated in a humidified atmosphere with 5% CO2 at 
37 °C. After 24 h of cell adhesion, the cells were treated 
with test compounds at concentrations ranging from 400 
to 6.25 μM, dissolved in DMSO (0.5%). Next 24, 48 and 
72 h of incubation, stock MTT solution (5 mg/mL in PBS) 
was added to each well and were incubated for more 2 h 
at 37 °C. Subsequently, 100 μL of DMSO was added to 
dissolve the insoluble purple formazan, and the OD of each 
well was measured at 570 nm. Three wells per dose were 
analyzed for each sample in three different experiments, 
and the results were expressed as the percentage of viable 
cells in comparison to negative control (untreated cells). 
The cytotoxicity of each test compound was expressed as 
CC50, the cytotoxic concentration of sample that inhibited 
cell growth by 50%.
Statistical analysis
All analyses were accomplished in triplicate and 
results were expressed as mean ± standard deviation (SD). 
SCHEME 1 - Synthesis of derivatives 1a-8b. For the compounds 1a,1b; 3a,3b; 5a,5b; 7a,7b, the UA and BA were submitted 
separately at followed reactions: (a) dichloromethane, acetic anhydride, pyridine, rt., 24h; (b) acetone, Jones Reagent at 0 °C, rt., 
3h; (c) butyric anhydride, DMAP, rt., 24h; (d) isobutyric anhydride, DMAP, rt., 24h. For the compounds 2a, 2b; 4a, 4b; 6a, 6b; 8a, 
8b, the synthetic route followed this condition: (e) dichloromethane, oxalyl choride, N2 atmosphere, 0 °C, 3h. -  trimethylamine, 
0 °C - imidazole, rt., 24h.
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The data were subjected to one-way analysis of variance 
(ANOVA) and P-values below 0.05 were regarded as 
significant. Dunnett’s multiple comparisons test was used 
to identify significant differences between means among 
the different treatments (GraphPad Prism Software). 
RESULTS AND DISCUSSION
The worldwide incidence rates of infection 
by Leishmania spp. and T. vaginalis are startling. 
Leishmaniasis and trichomoniasis are not notifiable 
diseases in all the countries where these diseases are 
endemic and any surveillance system is available to detect 
resistance. Therefore, a substantial number of cases of 
these diseases are underestimated, leading to neglected 
parasitic infection status (Choffnes, Relman, 2011). 
Previously, our research group evaluated the 
potential of some semisynthetic derivatives of pentacyclic 
triterpenes ursolic acid (UA) and betulinic acid (BA) 
against Leishmania spp. and Trichomonas vaginalis 
species. Seven UA derivatives were evaluated against 
the promastigote forms of L. amazonensis and the N-{3-
[4-(3-(Bis(4-hydroxybenzyl)amino)propyl)piperazinyl]
propyl}-3-O-acetylursolamide  (Figure 1) was the most 
active compound with EC50 = 10 µM (Gnoatto et al., 
2008a). Against T. vaginalis, among the six derivatives 
tested, the N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-
3-acetylbetulinamide (Figure 1) was active, with a MIC 
value of 91.2 μM (Innocente et al., 2014). Both active 
compounds have an acetyl group at C-3 and a piperazinyl 
at C-28 positions. Hence, in this study, we have evaluated 
the activity of different derivatives of UA and BA against 
these important neglected protozoa species.
Two series of ursolic acid and betulinic acid 
derivatives have been designed and semisynthetized 
by modifications at C-3 and C-28 positions, generating 
sixteen derivatives (Figure 2). When they were evaluated 
against T. vaginalis (Figure 3), at 100 µM, it was observed 
that the compound 1b, which is acetylated at C-3, reduces 
the parasite viability at 74%, followed by the compounds 
oxidized at C-3 (3a and 3b) (55% of viability reduction). 
The modifications at C-28 (2a, 2b; 4a, 4b; 6a, 6b; 8a, 8b) 
were especially not favorable for the anti-T. vaginalis 
activity. In the analysis of EC50 of some active compounds, 
betulin presented an EC50 value of the 60 µM, and the 
compounds 1b and 5b, 30 µM and 50 µM, respectively.
Among the derivatives tested against L. amazonensis, 
at concentration of the 100 µM, three compounds 
presented reductions of viability below 50% (7a, 7b, 
betulin) (Figure 4). For these compounds, the EC50 
values were evaluated; betulin presented an EC50 value 
of the 72.2 µM, and the compounds 7a and 7b, 85.7 µM 
and 119.4 µM, respectively. Differently from what was 
reported by Gnoatto et al. (2008b), who found a significant 
UA anti-promastigote activity (EC50 = 20 µM) in the tested 
conditions, UA was not active against L. amazonensis 
promastigotes. Considering the concentration tested, data 
is in agreement with Peixoto et al. (2011), which showed 
anti-L. amazonensis activity for UA in concentration 
higher than 100 µM (EC50 = 360.3 µM). Although the 
extraction of UA is simple and inexpensive, since the 
raw material is obtained from residue of apple juice 
manufacture (Cargnin, Gnoatto, 2017), the EC50 value 
is outlying of the range considered acceptable in the 
development of new semisynthetic drug.
The triterpene BA presented a carboxylic acid at 
C-28 and betulin, another triterpene with a lupane skeleton, 
presented an alcohol group at position C-28 (R2). The 
leishmanicidal activity of betulin was evaluated and it was 
more active than compounds of BA series, with reduction 
FIGURE 1 – Compounds previously tested: 1. N-{3-[4-(3-(Bis(4-hydroxybenzyl)amino)propyl)piperazinyl]propyl}-3-O-
acetylursolamide; 2. N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-acetylbetulinamide; 3. 3β,6β,16β-trihydroxylup-20(29)-ene; 
4. 3β,6β,16β-trihydroxylup-20(29)-ene derivative, with 2 acetyl groups. 
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of promastigote forms of 68.7% (Figure 4). The activity 
was more than 20% higher than the most active compound 
of BA series. Therefore, taking into account the structure-
activity relationship, the hydroxyl groups in triterpenes 
skeleton seem to be important for anti-leishmanial activity. 
Corroborating with this hypothesis, previous studies 
revealed that lupane-triterpene (3β,6β,16β-triidroxilup-
20(29)-ene) (Figure 1) isolated from Combretum leprosum 
fruit extracts, exhibited a significant anti-leishmanial 
activity against L. amazonensis promastigotes, with an 
EC50 of 7.2 µM, and is also effective in eliminating the 
L. (L.) amazonensis intracellular amastigotes at 109 
μM (Teles et al., 2011; Teles et al., 2015). Moreover, a 
synthetic derivative with two hydroxyl groups replaced 
by acetyl (Figure 4), became inactive (Teles et al., 2011). 
Considering the evaluation of the in vitro cytotoxicity 
FIGURE 2 – Semisynthetic derivatives of UA and BA series.
FIGURE 3 – Anti-T. vaginalis activity of UA and BA derivatives. Each bar represents the mean ± standard deviation of at least three 
independent experiments. Statistically significant differences (p ≤ 0.05) between treated and non-treated groups are indicated by (*).
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of these compounds on mammalian cells (VERO 
cells) at 24, 48 and 72 h, the UA presented cytotoxic 
effect of CC50 200, CC50 101.64, and CC50 99.91 µM, 
respectively. The other compounds tested were not 
cytotoxic (CC50 > 400 µM). Even though the compounds 
were not cytotoxic in this cellular model, some structure 
modifications are necessary to improve the activity profile 
towards parasites.
Therefore, further studies are required to develop 
UA and BA derivatives with more potent leishmanicidal 
and trichomonicidal properties. Nevertheless, in the 
test conditions, the derivatives investigated did not 
exhibit pronounced activity against T. vaginalis and L. 
amazonensis, these preliminary results showed that, based 
on structure-activity relationship, triterpenes could be a 
source of novel anti-leishmanial and anti-trichomonas 
agents. Hence, the delineation of additional semisynthetic 
modifications, especially including polar groups, such 
as hydroxyl groups, in the skeletons could improve the 
activity of these compounds.
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